Teva Pharmaceutical Industries annual operating margin
2007
2008
2009
2010
2011
2012
2013
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Operating Margin Growth & History (TEVA)
Teva Pharmaceutical Industries's operating margin was 12.50% for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 12.50% | +14.33 pp |
| 2024 | 2024-12-31 | −1.83% | −4.56 pp |
| 2023 | 2023-12-31 | 2.73% | +17.45 pp |
| 2022 | 2022-12-31 | −14.72% | −25.53 pp |
| 2021 | 2021-12-31 | 10.81% | +32.25 pp |
| 2020 | 2020-12-31 | −21.44% | −18.82 pp |
| 2019 | 2019-12-31 | −2.62% | +6.34 pp |
| 2018 | 2018-12-31 | −8.96% | −17.08 pp |
| 2013 | 2013-12-31 | 8.12% | −2.74 pp |
| 2012 | 2012-12-31 | 10.85% | −6.12 pp |
| 2011 | 2011-12-31 | 16.98% | −7.03 pp |
| 2010 | 2010-12-31 | 24.01% | +9.09 pp |
| 2009 | 2009-12-31 | 14.92% | +4.59 pp |
| 2008 | 2008-12-31 | 10.33% | −15.13 pp |
| 2007 | 2007-12-31 | 25.46% | — |
Teva Pharmaceutical Industries quarterly operating margin
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −5.58% | −16.47 pp |
| Q1 2026 | 2026-03-31 | 16.37% | +3.04 pp |
| Q4 2025 | 2025-12-31 | 6.39% | +7.08 pp |
| Q3 2025 | 2025-09-30 | 19.69% | +20.86 pp |
| Q2 2025 | 2025-06-30 | 10.90% | +11.02 pp |
| Q1 2025 | 2025-03-31 | 13.34% | +19.05 pp |
| Q4 2024 | 2024-12-31 | −0.69% | −17.65 pp |
| Q3 2024 | 2024-09-30 | −1.18% | −10.11 pp |
| Q2 2024 | 2024-06-30 | −0.12% | +16.74 pp |
| Q1 2024 | 2024-03-31 | −5.71% | −5.35 pp |
| Q4 2023 | 2023-12-31 | 16.96% | +41.53 pp |
| Q3 2023 | 2023-09-30 | 8.94% | −2.72 pp |
| Q2 2023 | 2023-06-30 | −16.86% | +8.20 pp |
| Q1 2023 | 2023-03-31 | −0.36% | +19.12 pp |
| Q4 2022 | 2022-12-31 | −24.57% | −26.45 pp |
| Q3 2022 | 2022-09-30 | 11.66% | −4.37 pp |
| Q2 2022 | 2022-06-30 | −25.07% | −39.95 pp |
| Q1 2022 | 2022-03-31 | −19.48% | −30.37 pp |
| Q4 2021 | 2021-12-31 | 1.88% | −7.24 pp |
| Q3 2021 | 2021-09-30 | 16.03% | +125.18 pp |
| Q2 2021 | 2021-06-30 | 14.88% | +10.41 pp |
| Q1 2021 | 2021-03-31 | 10.90% | +6.52 pp |
| Q4 2020 | 2020-12-31 | 9.12% | +5.80 pp |
| Q3 2020 | 2020-09-30 | −109.15% | −107.17 pp |
| Q2 2020 | 2020-06-30 | 4.47% | +19.89 pp |
| Q1 2020 | 2020-03-31 | 4.38% | +1.15 pp |
| Q4 2019 | 2019-12-31 | 3.31% | +82.89 pp |
| Q3 2019 | 2019-09-30 | −1.98% | −2.33 pp |
| Q2 2019 | 2019-06-30 | −15.42% | −15.12 pp |
| Q1 2019 | 2019-03-31 | 3.23% | −26.88 pp |
| Q4 2018 | 2018-12-31 | −79.58% | −86.31 pp |
| Q3 2018 · Sep 30 | 2018-09-30 | 0.35% | +100.70 pp |
| Q2 2018 · Jun 30 | 2018-06-30 | −0.30% | −16.14 pp |
| Q1 2018 · Mar 31 | 2018-03-31 | 30.11% | +16.36 pp |
| Q3 2018 · Sep 30 | 2017-09-30 | 6.73% | −0.44 pp |
| Q2 2018 · Jun 30 | 2017-06-30 | −100.35% | −124.57 pp |
| Q1 2018 · Mar 31 | 2017-03-31 | 15.84% | −5.10 pp |
| Q3 2017 | 2016-09-30 | 13.75% | +0.42 pp |
| Q2 2017 | 2016-06-30 | 7.17% | −7.87 pp |
| Q1 2017 | 2016-03-31 | 24.22% | +2.24 pp |
| Q3 2016 | 2015-09-30 | 20.94% | +2.61 pp |
| Q2 2016 | 2015-06-30 | 13.33% | −6.11 pp |
| Q1 2016 | 2015-03-31 | 15.03% | +4.72 pp |
| Q3 2014 | 2014-09-30 | 21.98% | +6.15 pp |
| Q2 2014 | 2014-06-30 | 18.33% | +30.24 pp |
| Q1 2014 | 2014-03-31 | 19.44% | +1.60 pp |
| Q4 2013 | 2013-12-31 | 10.31% | +4.15 pp |
| Q3 2013 | 2013-09-30 | 15.83% | +17.04 pp |
| Q2 2013 | 2013-06-30 | −11.90% | −32.07 pp |
| Q1 2013 | 2013-03-31 | 17.83% | −0.75 pp |
| Q4 2012 | 2012-12-31 | 6.16% | −4.59 pp |
| Q3 2012 | 2012-09-30 | −1.21% | −25.03 pp |
| Q2 2012 | 2012-06-30 | 20.16% | +5.99 pp |
| Q1 2012 | 2012-03-31 | 18.58% | −2.67 pp |
| Q4 2011 | 2011-12-31 | 10.75% | −6.77 pp |
| Q3 2011 | 2011-09-30 | 23.83% | −4.13 pp |
| Q2 2011 | 2011-06-30 | 14.17% | −14.12 pp |
| Q1 2011 | 2011-03-31 | 21.25% | −1.58 pp |
| Q4 2010 | 2010-12-31 | 17.52% | +10.68 pp |
| Q3 2010 | 2010-09-30 | 27.95% | +6.74 pp |
| Q2 2010 | 2010-06-30 | 28.29% | +7.64 pp |
| Q1 2010 | 2010-03-31 | 22.83% | +5.73 pp |
| Q4 2009 | 2009-12-31 | 6.84% | +21.31 pp |
| Q3 2009 | 2009-09-30 | 21.21% | −0.67 pp |
| Q2 2009 | 2009-06-30 | 20.65% | −1.95 pp |
| Q1 2009 | 2009-03-31 | 17.10% | +5.55 pp |
| Q4 2008 | 2008-12-31 | −14.47% | — |
| Q3 2008 | 2008-09-30 | 21.89% | — |
| Q2 2008 | 2008-06-30 | 22.60% | — |
| Q1 2008 | 2008-03-31 | 11.55% | — |
Teva Pharmaceutical Industries operating margin trends
Over the last five reported fiscal years, Teva Pharmaceutical Industries's operating margin increased from −21.44% to 12.50%, a change of +33.94 percentage points. The latest reported quarter, Q2 2026, shows −5.58%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries filings at SEC.gov ↗